Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KUR 211

Drug Profile

KUR 211

Alternative Names: I-020201; KUR-211

Latest Information Update: 21 Aug 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kuros Biosurgery
  • Developer Baxalta; Kuros Biosurgery
  • Class Blood proteins; Growth factors; Peptides
  • Mechanism of Action Platelet derived growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Diabetic foot ulcer

Most Recent Events

  • 21 Aug 2015 No recent reports on development identified - Phase-II for Diabetic foot ulcer in Europe (Topical)
  • 01 Sep 2011 Baxter and Kuro complete enrolment in their phase IIb trial for Diabetic foot ulcer in Europe
  • 07 Jul 2009 Phase-II clinical trials in Diabetic foot ulcer in Europe (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top